The multiple sclerosis (MS) drug alemtuzumab causes severe and unpredictable adverse events (AEs).
Getting to the guts of the matter for autism is exactly what a group of investigators, led by scientists at Arizona State University (ASU), hopes to accomplish with its novel approach to effective autism treatments by focusing on improving the gut microbiome through fecal microbial transplants. While initial results from a small human study are promising, additional testing will be necessary before an FDA-approved therapy would be available or recommended to the public.
In recognition of more than three decades of service, which includes a continuing commitment to Thailand and her community in Maryland, the American Dental Association has announced that Dr. Usa Bunnag has been named the 2017 ADA Humanitarian Award recipient.
As the demographic shift to an older population continues, a growing number of men and women will be diagnosed with osteoporosis. In addition to existing drug therapies, certain lifestyle and nutritional factors are known to reduce its risk.
Older women with low physical activity and 10 hours of daily sit time had even ‘older’ cells
The last few years have seen an avalanche of research focused on the microbiome the community of tiny microbes that live in our bodies and are believed to influence many diseases, including diabetes, obesity and cancer. But linking individual bacterium with particular disorders has proven to be challenging.
A study published in The New England Journal of Medicine provides compelling evidence that extensively drug-resistant tuberculosis (XDR TB) is spread from person-to-person in the KwaZulu-Natal province, South Africa from 2011–2014.
Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, has announced that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) has entered clinical trials at Wageningen University in the Netherlands for treatment of irritable bowel syndrome (IBS) with AXIM’s CanChew Plus® cannabidiol (CBD) gum.
ONE YEAR AFTER IMPLANT, 93 PERCENT OF PATIENTS WHO CONTINUED SCS THERAPY HAD LOWER AVERAGE DAILY MORPHINE-EQUIVALENT DOSES THAN PATIENTS WHO HAD THEIR SCS SYSTEM REMOVED